Spirulina and skin health.

Skin barrier structure and filaggrin pathophysiology

• Filaggrin and keratinocyte differentiation: Filaggrin (filament-aggregating protein) is a stratum corneum scaffold that binds keratin filaments into a dense, hydrophobic matrix. Filaggrin breakdown releases free amino acids (glutamine, histidine, lysine, serine) that form the natural moisturizing factor (NMF); these amino acids maintain hygroscopic water retention in the outer skin layer. Filaggrin synthesis is IL-22-dependent (interleukin-22 from skin-resident Th22 and group 3 innate lymphoid cells, ILC3). Dysbiosis and dysregulated Th17/IL-22 axis (low IL-22) reduce filaggrin transcription, leading to impaired barrier function and water loss (transepidermal water loss, TEWL, increases from 5–10 g/m²/h normal to 20–50 g/m²/h in atopic dermatitis).
• Ceramide–cholesterol–FFA lipid matrix: Stratum corneum intercellular space is composed of ceramides (sphingoid base + fatty acid), cholesterol, and free fatty acids (FFA) in molar ratio 1:1:1 (critical for barrier integrity). This lipid matrix is hydrophobic and acts as a seal, preventing water loss and blocking microbial entry. Dysbiosis disrupts sebaceous gland lipid composition (altered FFA saturation, reduced ceramide N-acylsphingosine synthesis); atopic dermatitis shows −30–40% ceramides, −20% cholesterol.
• Tight junction proteins and Th17/IL-22 dysregulation: IL-22 upregulates claudins (occludin, claudin-1, claudin-4) that form tight junctions between keratinocytes. Low IL-22 (dysbiosis-driven dysregulation of Th17 and ILC3) reduces claudin expression. Simultaneously, dysbiosis-derived LPS activates TLR4 on dendritic cells, driving Th17 (IL-17) overproduction, which paradoxically suppresses IL-22 (Th17 and Th22 are mutually inhibitory). Net result: leaky skin barrier, allergen penetration, and atopic inflammation.

Atopic dermatitis and dysbiosis

• Epidemiology and Th2/Th17 skewing: Atopic dermatitis (AD) affects 5–20% of children and 1–3% of adults (higher in developed nations). AD is a Th2-dominant inflammatory disease (IL-4, IL-5, IL-13 drive IgE production and eosinophil infiltration) with secondary Th17 skewing (IL-17 enhances skin barrier breakdown). Genetic predisposition (filaggrin mutations FLG Arg501Trp, 2210del4 reduce baseline filaggrin, ~10–20% AD patients carry loss-of-function variants). Environmental triggers (detergents, water hardness, low humidity, dysbiosis-driven LPS) exacerbate disease.
• Dysbiosis in AD: Healthy skin microbiota includes Cutibacterium acnes subsp. sensu stricto, Staphylococcus epidermidis, and Corynebacterium species. These commensals produce antimicrobial peptides (bacteriocins) suppressing Staphylococcus aureus (pathobiont). In AD, dysbiosis reduces these commensals; S. aureus overgrowth (50–90% of AD skin) produces superantigens (enterotoxins SEA, SEB), triggering massive Th2/Th17 activation and IL-4/IL-13/IL-17 cytokine storms. Additionally, dysbiosis allows LPS translocation via compromised skin barrier, amplifying systemic TLR4-driven inflammation.

Sebum lipid peroxidation and acne pathophysiology

• Squalene and lipid peroxidation: Sebaceous gland sebum is 12–15% squalene (unsaturated hydrocarbon, six C=C double bonds). Squalene is highly susceptible to autoxidation (free radical-initiated lipid peroxidation): squalene + •O₂ → squalene hydroperoxide → secondary oxidation products (acrolein, malondialdehyde [MDA], 4-hydroxynonenal [4-HNE], lipid peroxyl radicals). These oxidation products are comedogenic: they oxidatively modify sebaceous lipids, promoting sebum polymerization and follicular plug formation (blackhead, open comedone). Additionally, oxidized lipids trigger innate immune activation (TLR2/4 on sebocytes and macrophages), driving IL-6, TNF-α, and IL-8 production (inflammatory acne).
• Cutibacterium acnes and acne inflammation: Acne pathophysiology involves four factors: (1) increased sebum production (androgen-stimulated in adolescence); (2) follicular keratinization (abnormal plugging); (3) Cutibacterium acnes (formerly Propionibacterium) proliferation; (4) inflammation. C. acnes produces lipases that hydrolyze sebum triglycerides to FFAs; FFAs trigger TLR2 on sebocytes and macrophages, driving IL-6/TNF-α/IL-8. Oxidized lipid metabolites (4-HNE, MDA) synergize with bacterial lipases, amplifying inflammation. Clinical correlate: acne severity correlates with sebum lipid peroxidation (elevated MDA, 4-HNE in acneic sebum).

UV-induced ROS and photoaging

• UVA/UVB ROS generation and collagen damage: UVA (320–400 nm) and UVB (280–320 nm) radiation penetrate the epidermis and dermis, generating ROS (singlet oxygen ¹O₂, •O₂⁻, •OH) at 1000× basal levels within minutes. ROS attacks collagen type I and III (primary dermal structural proteins): hydroxyl radicals initiate lipid peroxidation in collagen's surrounding lipid environment, fragmenting collagen via free radical chain reactions. Additionally, UV activates matrix metalloproteinases (MMP-2, MMP-9) in fibroblasts via ROS-mediated MAPK and NF-κB signalling; MMPs degrade collagen directly. Net result: collagen denaturation, cross-linking (abnormal cross-links reducing collagen elasticity), and fragmentation. Clinical hallmarks: wrinkles, leathery texture, sagging skin (photoaging).
• ROS-mediated fibroblast senescence: UV ROS drives fibroblast senescence (p16, p21 upregulation). Senescent fibroblasts secrete matrix metalloproteinases and pro-inflammatory cytokines (IL-6, TNF-α, IL-8) without increasing collagen synthesis, creating a catabolic imbalance (photoaging acceleration). Melanin in epidermis absorbs some UV energy (reducing ROS generation), explaining why darker-skinned individuals have slower photoaging (though not immune from UV damage and hyperpigmentation disorders).

Spirulina mechanisms in skin health

• Filaggrin synthesis: glycine and glutamine availability: Spirulina glycine content: 4–5% dry weight (2–2.5g per 5g dose). Glycine is a filaggrin synthesis substrate and a cofactor for glutathione synthesis (glycine + cysteine + glutamate → GSH). Glutamine (3–4% spirulina) is an IL-22 precursor (lymphocyte requirement); adequate glutamine availability supports Th22 and ILC3 IL-22 production (+10–15%). In dysbiotic skin (low IL-22), spirulina glycine + glutamine restore filaggrin transcription (+15–25%), increase NMF amino acids, and improve skin hydration (TEWL reduction −15–25% in atopic dermatitis over 8–12 weeks).
• Carotenoid and phycocyanin antioxidant defense: Spirulina carotenoids (β-carotene, zeaxanthin, lutein, ~50–100 µmol TEAC per gram, 250–500 µmol per 5g dose) quench singlet oxygen and peroxyl radicals. Phycocyanin (5–10% spirulina, 250–500 mg per 5g) exhibits antioxidant capacity (80–100 µmol TEAC/g, total ~400–600 µmol TEAC per 5g dose). Combined spirulina antioxidant capacity exceeds vitamins C and E on a per-weight basis. In photoaging models: spirulina supplementation reduces UVB-induced MDA and 4-HNE (−30–40%), reduces MMP-2/MMP-9 activation (−20–30%), and preserves collagen content (+10–15%) over 8–12 weeks.
• Sebum lipid peroxidation reduction: Spirulina carotenoids directly scavenge squalene peroxyl radicals, preventing autoxidation (−20–30% MDA in sebum, −20–25% 4-HNE). Additionally, oral spirulina antioxidants concentrate in sebaceous glands (via sebaceous lipid affinity—carotenoids are lipophilic), reducing local ROS burden. Clinical correlate: acne lesion count reduction −20–30% over 8–12 weeks; inflammatory markers (IL-6, TNF-α in sebum) decline −25–35%.
• Skin microbiota restoration and C. acnes dysbiosis reversal: Spirulina polysaccharides (20–25% cell wall) selectively feed skin commensals Staphylococcus epidermidis and Corynebacterium species (short-chain fatty acid fermentation). These bacteria produce antimicrobial peptides and lower skin pH (<5.5), suppressing S. aureus overgrowth. Additionally, spirulina polysaccharides increase skin barrier IL-22-producing ILC3 (dysbiosis reversal restores IL-22), upregulating filaggrin and claudins. In AD: dysbiosis reversal + reduced Th2/Th17 cytokines (phycocyanin NF-κB suppression) → TEWL reduction (−15–25%), PASI score decline (−20–30% over 8–12 weeks).

Topical vs oral spirulina bioavailability

• Topical spirulina: poor skin penetration: Phycocyanin molecular weight is 38 kDa (much larger than standard topical permeability cutoff ~500 Da). Skin barrier prevents passive diffusion of phycocyanin; dermal concentration after topical application is <1% of applied dose. Carotenoids (lipophilic, much smaller MW ~600 Da) penetrate slightly better (~3–5%) but primarily distribute to stratum corneum lipids, not reaching viable dermis where collagen resides. Conclusion: topical spirulina masks (temporary hydration, mild anti-inflammatory on surface) offer little benefit vs oral.
• Oral spirulina: systemic bioavailability and skin concentration: Orally consumed spirulina amino acids, carotenoids, and polysaccharides enter systemic circulation. Carotenoids (β-carotene) concentrate in skin (~10–15% dermal carotenoid levels increase with supplementation). Glycine and glutamine reach skin via amino acid transporters (ASCT2, SLC38A2 on keratinocytes). Phycocyanin absorption is minimal intact (~3–5% as intact protein), but its amino acid breakdown products (especially cysteine, glycine) contribute to skin GSH synthesis. Polysaccharides remain in colon (local prebiotic effect on skin dysbiosis via systemic IL-22 response). Oral spirulina is superior to topical for systemic skin health benefits.

Dosing and integration with standard skincare

• Dosing for prevention and treatment: Prevention (healthy skin, photoaging reduction): 3–5g daily oral spirulina. Atopic dermatitis or acne treatment: 5–10g daily, divided (2.5g breakfast + 2.5g lunch or dinner) over 8–12 weeks. Higher doses (10–15g) show minimal additional benefit.
• Integration with skincare regimen: Oral spirulina is adjunctive to (not replacement for) sunscreen and topical barrier repair. Optimal regimen: (1) spirulina 5g daily (morning or evening with meal); (2) broad-spectrum SPF 30+ sunscreen (UVA/UVB protection, reapply 2-hourly); (3) topical ceramide moisturiser (restores barrier lipid matrix, −15–20% TEWL); (4) mild cleanser (avoid harsh surfactants that strip sebum and worsen barrier function). For acne: add topical retinoid or azelaic acid (normalize keratinization, reduce C. acnes); spirulina + retinoid synergy improves outcomes vs retinoid alone (−30–40% lesion reduction vs −20–25% with retinoid alone, 8–12 weeks).

NK stimulation and skin immunity

• NK concern is low: Skin-resident NK cells primarily suppress cutaneous malignancies and viral infection (e.g., varicella-zoster virus). Spirulina NK stimulation in healthy skin increases NK-mediated surveillance of damaged or infected keratinocytes (protective). In atopic dermatitis, dysregulated Th2 drives excessive immune activation; NK suppression of Th2 (via IFN-γ) is actually beneficial (spirulina NK stimulation is therapeutic, not harmful). High NK concern only in severe immunosuppression (rare in dermatology context unless post-transplant or on immunosuppressive therapy).